LG is a 28 year old female who has been on a combination oral contraception, ethinyl estradiol (EE) 30mcg and levonorgestrel, a second generation progesterone, for 6 months. She is experiencing some weight gain and acne. She is not experiencing any breakthrough bleeding. Based on the safety and adverse event profile, which would be the BEST option to change LG's COC to? Select one:

Combined oral contraceptives (COCs) contain estrogen and progestin components that influence both contraceptive efficacy and side effect profiles. Androgenic side effects such as acne and weight changes are commonly associated with second-generation progestins due to their higher androgen receptor activity. Selecting an alternative formulation often involves switching to a progestin with lower androgenic activity while maintaining adequate cycle control and contraceptive effectiveness. The goal is to improve tolerability without compromising safety or efficacy. Rationale: A. Androgenic side effects from Levonorgestrel do not reliably resolve over time in many patients, especially when related to intrinsic androgen receptor activity. Waiting without changing therapy may prolong bothersome acne and weight concerns, reducing adherence and satisfaction. Clinical improvement is more likely achieved through changing the progestin component rather than expecting spontaneous resolution. B. Lowering the ethinyl estradiol (EE) dose while continuing Levonorgestrel may reduce estrogen-related side effects but does not significantly address androgenic effects such as acne. In some cases, reducing estrogen may worsen breakthrough bleeding without improving acne. Therefore, this option does not effectively target the patient’s main concern. C. A progesterone-only contraceptive such as Norethindrone is not appropriate in this scenario because it eliminates estrogen, which plays a role in cycle regulation and acne control. Progestin-only pills can also cause irregular bleeding and may not improve androgenic side effects. This option does not optimize both safety and symptom management for the patient’s presentation. D. Switching to a formulation containing Desogestrel while maintaining EE 30mcg is the best option because third-generation progestins have lower androgenic activity compared to levonorgestrel. This change is more likely to improve acne and weight-related concerns while maintaining good cycle control and contraceptive efficacy. It balances symptom management with continued reliable contraception.